Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function

Apolipoprotein A-I (apoA-I) and apoA-I mimetic peptides inhibit tumor development in a mouse model of ovarian cancer

(2010) F. Su et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structure and Function of HDL Mimetics

(2009) Mohamad Navab et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

HDL as a Biomarker, Potential Therapeutic Target, and Therapy: FIG. 1.

(2009) Mohamad Navab et al.   DIABETES

A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acids

(2009) Mohamad Navab et al.   JOURNAL OF LIPID RESEARCH

In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide

(2009) Nosratola D. Vaziri et al.   KIDNEY INTERNATIONAL

The role of dysfunctional HDL in atherosclerosis

(2008) Mohamad Navab et al.   JOURNAL OF LIPID RESEARCH

Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I

(2008) Brian J. Van Lenten et al.   JOURNAL OF LIPID RESEARCH

Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients

(2008) LeAnne T. Bloedon et al.   JOURNAL OF LIPID RESEARCH